Singh Ravinder J, Taylor Robert L, Reddy G Satyanarayana, Grebe Stefan K G
Department of Laboratory Medicine, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA.
J Clin Endocrinol Metab. 2006 Aug;91(8):3055-61. doi: 10.1210/jc.2006-0710. Epub 2006 May 23.
We have recently introduced liquid chromatography-tandem mass spectrometry (LC-MS/MS) for 25-hydroxyvitamin D(2) (25OHD(2)) and 25OHD(3) testing. During subsequent clinical use, we identified significantly elevated results in some infants. We hypothesized this might represent assay interference caused by C-3 epimers of 25OHD(2) or 25OHD(3).
Our aims were to 1) determine the prevalence of C-3 epimers of 25OHD(2) or 25OHD(3) in human serum, and 2) identify the patient populations that might be affected.
We modified our LC-MS/MS method to allow detection of C-3 epimers. We retested specimens from four patient groups with the new method and an extracted RIA: 1) children less than 1 yr old, 2) children 1-18 yr old, 3) adults aged 20-87 yr with liver disease, and 4) adults aged 19-91 yr without liver disease.
In 172 children from group 1 with detectable 25OHD(2) or 25OHD(3), we identified C-3 epimers in 39 (22.7%). The epimers contributed 8.7-61.1% of the total 25-OHD. There was an inverse relationship between patient age and epimer percentage (r = 0.48; P < 0.002). The RIA gave accurate 25-OHD results that correlated with the modified LC-MS/MS method. No C-3 epimers were detected in any of the other groups.
Significant concentrations of C-3 epimers of 25OHD(2) or 25OHD(3) are commonly found in infants. This can lead to overestimation of 25-OHD levels. Measurements in children less than 1 yr should therefore be performed with an assay that allows accurate detection of 25-OHD in the presence of its C-3 epimers.
我们最近引入了液相色谱 - 串联质谱法(LC-MS/MS)用于检测25-羟基维生素D2(25OHD2)和25OHD3。在随后的临床应用中,我们发现一些婴儿的检测结果显著升高。我们推测这可能是由25OHD2或25OHD3的C-3差向异构体引起的检测干扰。
我们的目标是:1)确定人血清中25OHD2或25OHD3的C-3差向异构体的患病率,以及2)确定可能受影响的患者群体。
我们改进了LC-MS/MS方法以检测C-3差向异构体。我们用新方法和提取放射免疫分析法(RIA)对四组患者的样本进行重新检测:1)小于1岁的儿童,2)1 - 18岁的儿童,3)20 - 87岁患有肝病的成年人,以及4)19 - 91岁无肝病的成年人。
在第1组中可检测到25OHD2或25OHD3的172名儿童中,我们在39名(22.7%)儿童中检测到了C-3差向异构体。这些差向异构体占总25-OHD的8.7% - 61.1%。患者年龄与差向异构体百分比之间呈负相关(r = 0.48;P < 0.002)。RIA给出的25-OHD结果准确,与改进后的LC-MS/MS方法相关。在其他组中均未检测到C-3差向异构体。
婴儿中常见25OHD2或25OHD3的C-3差向异构体的显著浓度。这可能导致25-OHD水平的高估。因此,对于小于1岁的儿童,应使用能够在存在C-3差向异构体的情况下准确检测25-OHD的检测方法进行测量。